Clinical trial NCT05182034: Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis
Official title: A Multi-center, Randomized, Double-Blinded, Active-Controlled, Phase II Clinical Trial to Evaluate Efficacy and Safety of SMUP-IA-01 in Patients With Knee Osteoarthritis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Knee Osteoarthritis
Keywords: human umbilical cord blood derived mesenchymal stem cells
Knee Osteoarthritis
Lead sponsor: Medipost Co Ltd.
Sponsor class: INDUSTRY
First posted: 2022-01-10
Enrollment: 94
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This clinical trial is for patients who have been diagnosed with Kellgren-Lawrence (K\&L) Grade 2 or 3 knee osteoarthritis on radiographic examination. Only subjects who voluntarily agree to participate by filling out the written Informed Consent document will undergo screening for subject selection (inclusion/exclusion) criteria, at which time the severity of OA in each knee will be used to determined which knee will be treated (index knee - i.e., the more severely affected knee), and enroll in this study.

Detailed description: Patients who meet the inclusion/exclusion criteria will be randomly assigned at visit 2 to either of study group 1(low-dose), study group 2 (mid-dose) or active control group at 1:1:1 ratio. Patients will be administered with investigational product. Investigational product will be administered into the to-be-treated (index) knee one time within 7 days after randomization.

All patients enrolled will be followed up a total of 6 times (1, 4, 8, 12, 24, and 52 weeks) for up to post-dose 12 months. The patients should visit the study facility according to the visit schedule, and will undergo safety evaluation (vital sign, laboratory test, etc.) and efficacy evaluation \[Western Ontario and McMaster Universities osteoarthritis index (WOMAC), 100-mm visual analogue scale (VAS), International Knee Documentation Committee (IKDC) subjective knee evaluation\].

Eligibility criteria: Inclusion Criteria:

1. Patients who are ≥ 19 years of age on the date on which the consent form was signed
2. Patients diagnosed with knee osteoarthritis in at least one knee according to the clinical and radiological definition criteria of American College of Rheumatology (ACR) guidline at screening visit
3. Patients with knee OA corresponding to K\&L Grade 2 or 3 on radiographic examination at screening visit
4. Patients with less than 35 of BMI at screening visit
5. Patients who voluntarily decide to participate and sign the consent form
6. Patients who have persistent symptoms despite having undergone a reasonable trial of standard therapy (i.e., for a minimum of 3 months)

Exclusion Criteria:

1. Patients with any of the following diseases.

   - infectious arthritis, autoimmune or inflammatory joint diseases, gout, recurrent pseudogout, Paget's disease, intra-articular displaced fracture, ochronosis, acromegaly, haemochromatosis, Wilson's disease, genetic disease (hyperkinesia etc.), genetic collagen disorder, etc.
2. Patients who have ever undergone surgery or radiotherapy in the knee joint area within the 12 weeks prior to the screening visit date, or who have not been recovered from its side effect yet.
3. Patients with SIF (Subchondral insufficiency fracture) corresponding to type II of the RPOA (rapidly progressive osteoarthritis).
4. Patients whose physical examination results show severe degree of ligament instability.
5. Patients who have ever been given any intraarticular drug injection (i.e., hyaluronic acid injection, etc.) in to-be-treated (index) knee within the 6 months, prior to the screening visit date.
6. Patients who have ever been given steroids via intraarticular injection in to-be-treated (index) knee within the 12 weeks prior to the screening visit date.
7. Patients who have ever taken medications or given therapy below within the past 2 weeks on the basis of screening visit date. However, if patients have 14 days of wash-out period, the patient is allowed to participate.

   * drugs containing the ingredient of glucosamine, chondroitin sulfate, or diacerein
   * drugs containing herbal ingredient or herbal drugs for knee OA pain relief
   * anti-inflammatory analgesics or NSAIDs (prescription/non-prescription drugs). (However, patients who take acetaminophen and have 3 days of wash-out period are allowed to participate.)
   * oral steroids
   * hospital physiotherpy or oriental medicine treatment (buhang, acupunture, moxibustion etc.)
8. Patients who have skin disease on injection site or who are judged inappropriate for intra-articular injection on to-be-treated knee.
9. Patients who are judged unsuitable for MRI scanning (3.0 Tesla or higher) due to an insertion of metal material (i.e., heart pacemaker, cerebral aneurysm clip, etc.) or obstructive phobia. However, patients who have an insertion of metal material that is not affected by the magnetic field is allowed to participate
10. Patients with clinically significant past or present illness as follows;

    * heart diseases (i.e., myocardial infarction, coronary artery bypass surgery, arrhythmia and other serious heart diseases, etc.)
    * uncontrolled hypertension (not controlled down to 140/90 mmHg or below even after treatment with 3 or more antihypertensive drugs)
    * kidney disease (i.e., chronic kidney failure, glomerulonephritis, etc.)
    * liver disease (i.e., acute or chronic liver disease such as cirrhosis, fatty liver, etc.)
    * endocrine diseases (i.e., thyroiditis, diabetes insipidus, Cushing's disease, etc.)
    * other serious systemic diseases
11. Patient with ongoing autoimmune disorder that requires treatment with an immunosuppressive medication
12. Patients with infection that requires administration of parenteral antibiotics
13. Patients with a history of mental illness or epilepsy
14. Patients who have been diagnosed with cancer within the 5 years prior to the screening visit date
15. Patients who have been given immunosuppressive drugs such as cyclosporin A or azathioprine within the 6 weeks prior to the screening visit
16. Patients with a history of allergic reactions to hyaluronic acid injections, cryoprotectant (dimethyl sulfoxide, DMSO), or gentamicin.
17. Patients who are pregnant or lactating, or patients who have a plan to become pregnant during the study period
18. Male or female patients who do not agree to avoid pregnancy or the use of appropriate contraceptive methods during the study period. But women who have given infertility surgery or who have passed menopause one year or more are allowed to participate without the consent for contraception.
19. Patients who have been given any other cell therapy products or who plan to do so during the study period.
20. Patients who have been given any other investigational products including device within the 3 months prior to the screening visit date.
21. Patients who are judged by the investigator as inappropriate for enrollment into the study, for any reasons other than the reasons specified above.

Primary outcomes:
measure: Change in the WOMAC(Western Ontario and McMaster University Osteoarthritis Index) total score at post-dose 52 weeks from baseline
timeFrame: Baseline, 52 week
Secondary outcomes:
measure: Change amount of WOMAC total score at post-dose 24 weeks from the baseline
timeFrame: Baseline, 24 week
measure: Chage amount of WOMAC score by item (pain, stiffness, physical function) at post-dose 24 weeks and 52 weeks from the baseline
timeFrame: Baseline, 24 week, 52 week
measure: Chage amount of 100-mm VAS((Visual Analogue Scale) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline
timeFrame: Baseline, 1 week, 4 week, 8 week, 12 week, 24 week, 52 week
measure: Chage amount of IKDC(International Knee Documentation Committee) at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks from the baseline
timeFrame: Baseline, 1 week, 4 week, 8 week, 12 week, 24 week, 52 week
measure: Change in the WOMAS(whole-organ magnetic resonance imaging score) at post-dose 52 weeks from the baseline
timeFrame: Baseline, 52 week
measure: Change in T2 mapping at post-dose 52 weeks from the baseline
timeFrame: Baseline, 52 week
measure: Change in K&L grade, joint space width, mechanical axis, and anatomical axis at post-dose 52 weeks from the baseline
timeFrame: Baseline, 52 week
measure: Change amount of biomarkers at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks against the baseline; serum CTX-I, Serum HA, Serum MMP-3, Urine CTX-I, Urine CTX-II.
timeFrame: baseline, 1 week, 4 week, 8 week, 12 week, 24 week, 52week
measure: Percentage of patients who took the rescue drugs and dosage at post-dose 1 week, 4 weeks, 8 weeks, 12 weeks, 24 weeks and 52 weeks
timeFrame: 1 week, 4 week, 8 week, 12 week, 24 week, 52week
Other outcomes:
Locations:
city: Gyeonggi-do
country: Korea, Republic of
facility: Seoul Nation University Bundang Hospital
city: Seoul
country: Korea, Republic of
facility: Gangnam Severance Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospita
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Myungchul Lee, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Severance Hospital
name: Chonghyuk Choi, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Seoul Nation University Bundang Hospital
name: Chongbum Chang, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Korea University Anam Hospital
name: Seungbum Han, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Gangnam Severance Hospital
name: Sunghwan Kim, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: